# Semaglutide dosage & reconstitution (5 mg vial)

Semaglutide dosage: calculations for a 5 mg vial use the same amounts described in the literature. Adding 1 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 5 mg Semaglutide
- **Final volume:** 1 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing

### Standard Weekly Escalation Schedule (1 mL = ~5 mg/mL)

| Study phase | Weekly dose | Units per injection (mL) |
|---|---|---|
| Weeks 1 to 4 | 250 mcg | 5 units (0.05 mL) |
| Weeks 5 to 8 | 500 mcg | 10 units (0.10 mL) |
| Weeks 9 to 12 | 1 mg (1000 mcg) | 20 units (0.20 mL) |
| Weeks 13 to 16 | 1.7 mg (1700 mcg) | 34 units (0.34 mL) |
| Weeks 17+ | 2.4 mg (2400 mcg) | 48 units (0.48 mL) |

Frequency: Once weekly, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 1 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 injections |
| 5 | 0.05 mL | 250 mcg | 20 injections |
| 10 | 0.10 mL | 500 mcg | 10 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 5 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 3 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 2 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 1 injection |

## Supplies Needed

**Semaglutide vials (5 mg each)**
- Standard Weekly Escalation Schedule, 12 weeks: Minimum 2 vials (7 mg required).
- Standard Weekly Escalation Schedule, 24 weeks: Minimum 7 vials (33 mg required).

**U-100 syringes (1 mL)**
- Standard Weekly Escalation Schedule, 12 weeks: 12 new syringes for 12 injections.
- Standard Weekly Escalation Schedule, 24 weeks: 24 new syringes for 24 injections.

**Bacteriostatic water**
- Standard Weekly Escalation Schedule, 12 weeks: 2 mL total (1 mL per vial) → 1 × 3 mL vials.
- Standard Weekly Escalation Schedule, 24 weeks: 7 mL total (1 mL per vial) → 3 × 3 mL vials.

**Alcohol swabs**
- Standard Weekly Escalation Schedule, 12 weeks: 24 minimum; one box of 100 covers the calculation.
- Standard Weekly Escalation Schedule, 24 weeks: 48 minimum; one box of 100 covers the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1) with 94% homology to native human GLP-1. This 31-amino-acid peptide (MW: 4113.58 Da) incorporates strategic modifications that extend its half-life: Structural Modifications: Substitution of Alanine by 2-aminoisobutyric acid (AIB) at position 8 Acylation at Lysine-26 with a C18 fatty acid via a spacer A hydrophobic side chain that facilitates binding to serum albumin (>99%) Molecular Mechanisms: GLP-1R receptor: Selective activation in pancreatic β-cells, hypothalamus, and gastrointestinal tract cAMP/PKA pathway: Increase in intracellular cyclic AMP → glucose-dependent insulin secretion Glucagon Suppression: Pancreatic alpha-cell inhibition during hyperglycemia Gastric Emptying: Delay Mediated by Vagal Signaling (70% Reduction) Central Satiety Activation of POMC/CART neurons in the hypothalamic arcuate nucleus Advanced Pharmacokinetics: Subcutaneous bioavailability: 89% Tmáx: 1-3 days post-injection Median life 165-184 hours (weekly administration) Renal clearance: <1% (primary proteolytic degradation) Steady state: 4-5 weeks

## Research FAQ

**Q: How does Semaglutide compare to other GLP-1 agonists?** R: It presents a higher affinity for GLP-1R (EC50: 0.38 nM vs 1-5 nM for liraglutide) and a 7-fold longer half-life, allowing for weekly administration versus daily.
**P: Is it compatible for research in combination with insulin?** A: Yes, studies show a synergistic effect on glycemic control with a 30% reduction in the required insulin dose (Aroda et al., 2017).
**Q: What biochemical markers should be monitored in prolonged studies?** R: Plasma glucose, HbA1c, C-peptide, glucagon, serum lipase, renal function (creatinine, BUN), and inflammatory markers (CRP, IL-6).
**P: What is the optimal timing for metabolic evaluations?** R: Steady state reached in 4-5 weeks; continuous glycemic measurements require at least 8 weeks for full effects.

## References

1. Wilding JPH et al. N Engl J Med 2021;384(11):989-1002. PMID 33567185
2. Aroda VR, et al. (2017) “Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine” – Lancet Diabetes Endocrinol 5(5):355-366. [PubMed: 28344112]
3. Wilding JPH, et al. (2021) “Once-Weekly Semaglutide in Adults with Overweight or Obesity” - The New England Journal of Medicine 384(11):989-1002. [PubMed: 33567185]
4. Marso SP, et al. (2016) “Semaglutide and Cardiovascular Outcomes in Diabetes” – The New England Journal of Medicine 375(19):1834-1844. [PubMed: 27633186]
5. Cai HY, et al. (2018) “GLP-1 treatment protects Alzheimer model through enhancing neuronal insulin signaling” – Brain Res 1678:64-72. [PubMed: 29128461]
6. Novo Nordisk Research (2017) “Pharmacokinetic properties of semaglutide” – Diabetes Obes Metab 19(1):140-147.

---
Source: https://protocolopeptidos.com/en/compuestos/semaglutide-5mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.